NRAS Mutation Detection Kit
The RAS proto-oncogenes (HRAS, KRAS and NRAS) encode a family of GDP/GTP-regulated switches that convey extracellular signals to regulate the growth and survival properties of cells. GTP-bound RAS transmits its signal through downstream EGFR signaling pathways, for example the RAF—MEK—ERK and PI3K—AKT cascades. RAS family members are frequently found in their mutated, oncogenic forms in human tumors. In total, activating mutations in the NRAS genes occur in 13〜25% of cutaneous melanomas, 1~6% of colorectal cancer and 1% of lung cancer, mainly in exons 2, 3 or 4. The mutation status of NRAS gene is relevant to drug resistance of colorectal cancers treated with anti-EGFZ? monoclonal antibodies. As a result, NRAS mutations detection supplies evidence for targeted clinical therapy of tumor patients, decreases cost and time of treatment.